Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
1349 On Other Exchanges
Symbol
Exchange
1349 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

shanghai fudan-zhangjiang-h (1349) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FUDAN-ZHANGJIANG-H (1349)

Related News

No related news articles were found.

shanghai fudan-zhangjiang-h (1349) Related Businessweek News

No Related Businessweek News Found

shanghai fudan-zhangjiang-h (1349) Details

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, and sells bio-pharmaceutical products in the People’s Republic of China. The company offers genetic engineering drugs, which include recombinant tissue type plasminogen activator for heart infarction; recombinant human lymphotoxin a-derivatives that has completed Phase II clinical trials for tumors; recombinant human tumor necrosis recipient Fc fusion protein (Etanercept) and high bio-activity recombinant human TNF receptor for arthritis; PTH that has completed Phase I clinical trials for osteoporosis; CD30-MMAE and Avastin, which are in pre-clinical study for tumors; Anti-sclerostin mab that is in pre-clinical study for Osteoporosis; and PCSK9 that is in pre-clinical study for hypercholesterolemia. It also provides photodynamic therapy drugs comprising Hemoporfin for port wine stain; Duteroporphyrin, a Phase II clinical trial product for tumors; Aminolevulinic acid that is in Phase II clinical trial for cervical diseases infected by HPV; and Aminolevulinic acid that has submitted for clinical trials, as well as is in pre-clinical study for treating brain gliomas and basal cell carcinoma diseases. In addition, the company offers liposomal drugs, including Libod, a doxorubicin liposome injection for tumors; Vincristine sulphate liposome that has completed Phase–I clinical trials for tumors; Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical study for tumors; and Xenon liposome, which is in pre-clinical study for strokes. Further, it provides Antenatal Screening Diagnostic Reagent for down’s syndrome, etc. Additionally, the company offers research and development of pharmaceutical projects, medical instruments, medical diagnostic products, and biological and medical technology. It has a strategic agreement with Shanghai Pharmaceutical Co., Ltd. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

498 Employees
Last Reported Date: 04/9/15
Founded in 1996

shanghai fudan-zhangjiang-h (1349) Top Compensated Officers

Chairman, General Manager, Co- Founder and Ch...
Total Annual Compensation: CNY2.0M
Co-Founder, Deputy General Manager and Execut...
Total Annual Compensation: CNY1.2M
Deputy General Manager and Executive Director
Total Annual Compensation: CNY1.2M
Compensation as of Fiscal Year 2013.

shanghai fudan-zhangjiang-h (1349) Key Developments

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Proposes Amendments to its Articles of Association

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. at the annual general meeting to be held on May 29, 2015, proposed amendments to the Articles of Association as deemed appropriate for the increase of the company's registered capital and to reflect the new share capital structure of the company under the intended allotment and issue of the shares of the company.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Reports Cash Flow Earnings Results for the Year Ended December 31, 2014

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. reported cash flow earnings results for the year ended December 31, 2014. Net cash generated from operating activities was RMB 88,359,000 against RMB 89,442,000 a year ago. Purchase of property, plant and equipment was RMB 44,089,000 against RMB 56,716,000 a year ago.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. reported consolidated earnings results for the year ended December 31, 2014. For the period, revenue was RMB 470.900 million against RMB 415.925 million a year ago. Operating profit was RMB 129.960 million against RMB 108.360 million a year ago. Profit before income tax was RMB 128.099 million against RMB 98.946 million a year ago. Profit attributable to shareholders of the company was RMB 118.258 million or RMB 0.1281 per basic and diluted share against RMB 87.218 million or RMB 0.1009 per basic and diluted share a year ago. EBITDA was RMB 155.748 million compared to RMB 124.212 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1349:HK $8.99 HKD -0.08

1349 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1349.
View Industry Companies
 

Industry Analysis

1349

Industry Average

Valuation 1349 Industry Range
Price/Earnings 56.7x
Price/Sales 14.2x
Price/Book 10.3x
Price/Cash Flow 56.7x
TEV/Sales 13.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANGHAI FUDAN-ZHANGJIANG-H, please visit www.fd-zj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.